Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals Inc. (NASDAQ: IONS) and Rosetta Genomics (NASDAQ: ROSG)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ionis Pharmaceuticals Inc. (NASDAQ: IONS) and Rosetta Genomics (NASDAQ: ROSG).

Ionis Pharmaceuticals Inc. (NASDAQ: IONS)

Cowen & Co. analyst Eric Schmidt reiterated a Hold rating on Ionis Pharmaceuticals Inc (NASDAQ: IONS) today. The company’s shares opened today at $26.80.

Schmidt wrote, “IONS disclosed that severe cases of thrombocytopenia have been associated with two.”

According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 16.1% and a 53.6% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Alexion Pharmaceuticals.

Ionis Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $39

.
Rosetta Genomics (NASDAQ: ROSG)

Cantor Fitzgerald analyst Bryan Brokmeier reiterated a Buy rating on Rosetta Genomics Ltd (NASDAQ: ROSG) today. The company’s shares opened today at $1.16, close to its 52-week low of $0.71.

According to TipRanks.com, Brokmeier is a 4-star analyst with an average return of 7.1% and a 55.7% success rate. Brokmeier covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Given Imaging Ltd, and Laboratory Corp.

Rosetta Genomics Ltd has an analyst consensus of Moderate Buy

.